Genetic landscape of autism spectrum disorder in Vietnamese children by Tran, KT et al.
Ge n e tic  lan d sc a p e  of a u ti s m  
s p e c t r u m  diso r d e r  in Vietn a m e s e  
c hild r e n
Tra n,  KT, Le, VS, Bui, HTP, Do, DH, Ly, HTT, N g uye n,  HT, Dao,  
LTM, N g uy e n,  HT, Vu, DM, H a ,  LT, Le, HTT, M uk ho p a d hy ay, A a n d  
N g uy e n,  LT
h t t p://dx.doi.o r g/10.1 0 3 8/s4 1 5 9 8-0 2 0-6 1 6 9 5-8
Tit l e Ge n e tic  land sc a p e  of a u tis m  s p ec t r u m  diso r d e r  in 
Vietn a m e s e  child r e n
Aut h or s Tra n,  KT, Le, VS, Bui, HTP, Do, DH, Ly, HTT, N g uye n,  HT, 
Dao, LTM, N g uye n,  HT, Vu, DM, H a ,  LT, Le,  HTT, 
M uk ho p a d hy ay, A a n d  N g uye n,  LT
Typ e Article
U RL This  ve r sion  is available  a t :  
h t t p://usir.s alfor d. ac.uk/id/e p rin t/56 7 6 3/
P u bl i s h e d  D a t e 2 0 2 0
U SIR is a  digi t al collec tion  of t h e  r e s e a r c h  ou t p u t  of t h e  U nive r si ty of S alford.  
Whe r e  copyrigh t  p e r mi t s,  full t ex t  m a t e ri al  h eld  in t h e  r e posi to ry is m a d e  
fre ely availabl e  online  a n d  c a n  b e  r e a d ,  dow nloa d e d  a n d  copied  for  no n-
co m m e rcial p riva t e  s t u dy o r  r e s e a r c h  p u r pos e s .  Ple a s e  c h e ck  t h e  m a n u sc rip t  
for  a ny fu r t h e r  copyrig h t  r e s t ric tions.
For  m o r e  info r m a tion,  including  ou r  policy a n d  s u b mission  p roc e d u r e ,  ple a s e
con t ac t  t h e  Re posi to ry Tea m  a t :  u si r@s alford. ac.uk .
1Scientific RepoRtS |         (2020) 10:5034  | https://doi.org/10.1038/s41598-020-61695-8
www.nature.com/scientificreports
Genetic landscape of autism 
spectrum disorder in Vietnamese 
children
Kien trung tran1, Vinh Sy Le1,2*, Hoa thi phuong Bui3, Duong Huy Do3, Ha thi thanh Ly3, 
Hieu thi nguyen1, Lan thi Mai Dao1, thanh Hong nguyen1, Duc Minh Vu3, Lien thi Ha3, 
Huong thi thanh Le3, Arijit Mukhopadhyay4 & Liem thanh nguyen1*
Autism spectrum disorder (ASD) is a complex disorder with an unclear aetiology and an estimated 
global prevalence of 1%. However, studies of ASD in the Vietnamese population are limited. Here, we 
first conducted whole exome sequencing (WES) of 100 children with ASD and their unaffected parents. 
Our stringent analysis pipeline was able to detect 18 unique variants (8 de novo and 10 ×-linked, all 
validated), including 12 newly discovered variants. Interestingly, a notable number of X-linked variants 
were detected (56%), and all of them were found in affected males but not in affected females. We 
uncovered 17 genes from our ASD cohort in which CHD8, DYRK1A, GRIN2B, SCN2A, OFD1 and MDB5 
have been previously identified as ASD risk genes, suggesting the universal aetiology of ASD for 
these genes. In addition, we identified six genes that have not been previously reported in any autism 
database: CHM, ENPP1, IGF1, LAS1L, SYP and TBX22. Gene ontology and phenotype-genotype analysis 
suggested that variants in IGF1, SYP and LAS1L could plausibly confer risk for ASD. Taken together, this 
study adds to the genetic heterogeneity of ASD and is the first report elucidating the genetic landscape 
of ASD in Vietnamese children.
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders that includes autism, Asperger’s 
syndrome and pervasive developmental disorder not otherwise specified and is characterized by restricted repet-
itive behaviour, delays in language development and lack of reciprocal social communication and interaction1. 
The common psychiatric and cognitive comorbidities with ASD include intellectual disability (ID)2–4, sleep dep-
rivation5,6 and epilepsy (EP)3,7.
Recent studies have gradually emphasized the role of genetics in ASD, with up to 25% of ASD cases hav-
ing genetically identifiable causes8. Males have a 4-fold higher incidence of ASD than females9, suggesting the 
involvement of genetics in the aetiology of ASD. Previous studies have shown that 5% to 15% of patients with 
ASD have inherited copy number variations (CNVs) or de novo CNVs in some affected genes with synaptic 
function10. Genome-wide association studies have indicated that common variations are risk factors for ASD11,12. 
Meanwhile, de novo CNV and loss of function (LoF) mutations merely explain 2.6% of the variance in liability12. 
Other studies have revealed that non-coding de novo mutations in the promoter regions also affect ASD13,14. 
Recent genomic studies with large samples have explored new genes linked to ASD15,16. To date, over 100 genes 
have been identified as strongly linked to the risk of ASD17,18 and enriched in the following three main pathways: 
chromatin remodelling, transcription and splicing, and synaptic function18–20. In fact, ASD is highly genetically 
heterogeneous due to multiple familial inheritance patterns and the occurrence of a large number of de novo vari-
ations. It is estimated that up to 1000 genes are potentially implicated ASD21,22, making it one of the most complex 
disorders. Genetic factors are known to play an important role in ASD aetiology, but that their elucidation is a 
work in progress23–25.
The prevalence of ASD has been recently reported as high as 16.8 per 1000 or 1/59 children in the US9. Unlike 
that in Western populations, ASD is not well studied in Asia, where the prevalence of ASD varies from studies and 
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populations, ranging from 0.09–1.07% in south Asia26, 0.1018% in China27 and 2.64% in Korea4. Another study 
estimated that the prevalence of ASD in Asia from 1980 to recent present is 14.8/10,000 children28. A comprehen-
sive study on 17,277 children aged 18 to 30 months in Vietnam revealed that the prevalence was 0.752%, and the 
number continues to increase29. It is estimated that ASD affects from 1% to 2% of the global population4,30,31. The 
reason for the varied prevalence of ASD across populations remains unclear, although sociodemographic factors 
such as socioeconomic status, ethnicity and parental education level have been reported to influence the diagnosis 
of ASD, resulting in disparities in ASD prevalence across populations32–36. With an increasing number of new var-
iants/genes associated with ASD and different prevalence rates of ASD, we wanted to help shed light on whether 
genetic variation linked to ASD varies between populations. Thus, we conducted whole exome sequencing (WES) 
using a trio-based approach to investigate the genetic pattern of Vietnamese children with ASD.
Results
Clinical characteristics. We initially recruited 105 children who were definitively diagnosed with ASD and 
their unaffected parents. However, five families dropped out during recruitment. Finally, 100 trios were selected 
to participate in this study. In general, observations across populations, including Vietnamese populations, indi-
cate that the ASD-affected male/female (M/F) ratio is approximately 4-fold29,37,38. The ratio of M/F with ASD in 
our study was slightly higher than this value (M/F: 4.9-fold). By the enrolment time, the proband’s age ranged 
from 3 to 17 years old (y/o). The average age was 6.9 y/o (Supplementary Table S1). The CARS scores ranged from 
35 to 55.5, with an average score of 46.8 points. The DSM-V results showed that most probands were ranked at 
level 3 or required very substantial support, accounting for 68% of the cases. Denver II, comprising five domains 
including “Personal-social”, “Fine motor”, “Gross motor”, “Understanding” and “Language”, indicated that all 
probands had a lower developmental level compared to their chronological age. Overall, our cohort included 
ASD patients from mild to severe levels (Supplementary Table S1).
In addition to common autistic symptoms such as repetitive behaviours, speech delay, jargon, hyperactivity, 
toe walking and spinning, a quarter of the probands exhibited comorbid conditions such as ID (13 probands), 
EP (two probands), seizure (seven probands), ADHD (three probands) and cerebral palsy (CP) (one proband). 
Two cases showed congenital foot defects (ASD025 and ASD082) (Supplementary Table S1). Notably, six sub-
jects had siblings with ASD (ASD004, ASD027) or with other neurological conditions, such as speech delay, 
CP and ID (ASD062, ASD065, ASD072 and ASD075). Of these, proband ASD004 and his male sibling were 
twins conceived through in vitro fertilization (IVF), while proband ASD027 and his sibling were monozygotic 
twins (Supplementary Table S1). Twenty-three probands showed language regression during their early life. Six 
probands often experienced gastrointestinal (GI) problems, mostly chronic constipation and diarrhoea. We were 
able to perform brain fluorodeoxyglucose (FDG)-PET/CT indicating hypometabolism of 29 probands and brain 
MRI of 40 cases (Supplementary Table S1). Brain MRI in 15 probands showed abnormal signal changes, while the 
rest showed either no abnormality detected or unavailable information.
Screening of Rett and Fragile-X syndrome. Rett syndrome (MIM#312750) is a severe neurodevel-
opmental disorder that almost exclusively affects females. The disease is caused by heterozygous mutations in 
the X-linked MECP2 gene, which encodes methyl-CpG binding protein 2. We screened all 17 ASD females for 
mutations in exons 2, 3 and 4 of the MECP2 gene but did not find any potential causal variants. In other aspect, 
Fragile-X syndrome (MIM#30064) is caused by an expansion repeat of CGG in the 5′ UTR of the FMR1 gene. 
This syndrome is a common comorbid condition with ASD as well as ID39–41. Therefore, we next screened for this 
syndrome in all 100 children with ASD. Surprisingly, no subjects in our study had changes in the FMR1 gene. The 
patients with no mutations found in these two screening tests and their parents were then selected for the WES 
experiment.
Variant identification. Paired-end sequencing resulted in 36.4 billion reads from 100 trios with an aver-
age Q30 score of 95.2. The average sequencing depth in the target region of all samples was 83×, ranging from 
52 to 146.7× (Supplementary Table S2). All samples passed the quality control recommended by the manu-
facturer (Illumina). Although all the parents had self-claimed that they were biological parents to their chil-
dren, our relatedness analysis revealed unclear parental relations in four cases (ASD080, ASD091, ASD100 and 
ASD101). In addition, the mother’s sample from case ASD034 was inadvertently sequenced twice (Supplementary 
Table S3). Therefore, we excluded these cases from the downstream analyses. Reads with low depth, variants with 
MAF > 0.1%, synonymous variants and variants predicted as benign, tolerated or neutral by PolyPhen-2, SIFT 
and MutationTaster were removed accordingly. We finally detected and Sanger validated a total of 18 unique var-
iants in 17 genes from 16 unrelated probands. X-linked variants predominated, accounting for 56% of the total, 
followed by de novo variants (44%) (Fig. 1a, Table 1, Supplementary Fig. S1).
We observed that only six variants were recorded in dbSNP (Build 152), and the remaining variants were newly 
uncovered (Table 1). Missense variants were the major events, accounting for 61% of the total detected variants, 
followed by frameshift (17%), in-frame deletion (11%) and stop gained variants (11%) (Fig. 1b). Interestingly, we 
found two different variants in the DMD gene from two unrelated probands (ASD057 and ASD059) (Tables 1, 
2). We used SnpEff, SIFT, PolyPhen-2, MutationTaster and CADD to predict the deleteriousness of the nucle-
otide changes. SnpEff predicted that five different variants detected from four individuals had a high impact 
(Table 2), and all of them were LoF variants (MDB5:c.14_15delAA, DYRK1A:c.601 C > T, GRIN2B:c.2208dupG, 
AGTR2:c.757 C > T and SCN2A:c.232delC), while the rest had a moderate impact. Two variants, DYRK1A: 
c.601 C > T (proband ASD038) and AGTR2:c.757 C > T (proband ASD046), had the highest CADD scores, 
suggesting these variants were most deleterious (Table 2). Two missense variants, CHM:c.866 T > C (proband 
ASD086) and SLC16A7:c.260 C > T (proband ASD097), were predicted to be benign by PolyPhen-2 but were 
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damaging by MutationTaster and SIFT. The remaining variants were predicted to be damaging or disease causing 
by all employed in silico tools (Table 2).
Phenotype-genotype analysis and biological function. In total, we obtained 17 different genes, which 
showed genetic predispositions from 16 unrelated probands. We used the three most popular autism databases, 
SFARI (https://gene.sfari.org/), AutDB42 and the syndromic category in AutismKB43, to investigate the associa-
tion of the detected genes with ASD. We found that 11/17 genes were previously reported in SFARI and AutDB 
(Table 3). Meanwhile, only four genes, AGTR2, ATRX, DMD and MBD5, were categorized as syndromic ASD 
genes in AutismKB. We next compared our genes to gene sets of ASD or other neurological disorders and found 
that CHD8, DYRK1A, GRIN2B, MBD5 and SCN2A overlapped with the ASD gene sets (FDR ≤ 0.1) reported in 
previous large-scale ASD studies44,45. CHD8, DYRK1A, GRIN2B and SCN2A were found in a gene set containing 
94 genes enriched in developmental disorders derived from the DECIPHER project46. Three genes (DYRK1A, 
GRIN2B and SCN2A) were found in the EP gene set47. Hence, these genes detected in our ASD cohort are highly 
implicated in ASD or other neurological disorders.
Interestingly, our data showed six ASD candidate genes, CHM, ENPP1, IGF1, LAS1L, SYP and TBX22, which 
have not been previously reported in the three aforementioned autism databases (Table 3). Human Phenotype 
Oncology (HPO) analysis showed that all of these candidate genes have been reported to be linked to human 
diseases (Table 3). Mutations in the IGF148,49, LAS1L50,51 and SYP52 genes have been found in patients with CP 
and ID. In our study, a de novo missense variant was detected in the IGF1 gene from a female proband (ASD006) 
whose language and intellectual status were regressed after 18 m/o. Her language and personal-social status were 
strongly delayed (Supplementary Table S1). Brain PET-CT showed a decrease in FDG uptake in the temporal 
lobe, bilateral hippocampus, prefrontal region and parietal lobe (Supplementary Tables S1,S4). IGF1 mutations 
have been previously found in individuals with hyperactivity and short intension48,49. Treatment with IGF1 or 
expression of SHANK3, which is associated with idiopathic ASD, may restore synaptic deficits in neurons from 
Phelan-McDermid syndrome53,54. We thus conferred that IGF1 deficiency may reduce the synaptic transmission 
of neurons.
We also found two X-linked variants in the LAS1L and SYP genes from a male proband (ASD076). SYP 
encodes synaptophysin, which is involved in the regulation of synaptic plasticity55. GO analysis also showed 
that this gene is involved in synaptic membrane activity (Fig. 2, Supplementary Table S5). Moreover, several 
SYP mutations with evidence of segregation have been reported in patients with X-linked nonsyndromic mental 
retardation52. Therefore, SYP is a plausible gene for ASD. In addition, LAS1L encodes the ribosomal biogene-
sis protein LAS1L, which is required for cell proliferation, ribosome biosynthesis of the 60 S ribosomal subunit 
and the maturation of 28 S rRNA56,57. Missense mutations in the LAS1L gene have been detected in individuals 
with Wilson-Turner X-linked mental retardation syndrome50 and in a proband with congenital lethal motor 
neuron disease51. Our proband showed language regression after 12 m/o. At 5 y/o, he remained nonverbal and 
progressively developed more severe symptoms (Supplementary Table S4). Brain PET-CT images showed severe 
hypometabolism in the hippocampus region and in the frontal lobe (Supplementary Table S1). Interestingly, we 
observed that two probands (ASD006, ASD076) who carried IGF1, SYP and LAS1L variants showed language 
regression and brain hypometabolism (Supplementary Tables S1,S4).
Gene ontology (GO) analysis of the 17 detected genes against 9996 gene sets derived from the Molecular 
Signatures Database (MSigDB) with a false discovery rate (FDR) <0.05 revealed that AGTR2, PLXNA3, ATRX, 
GRIN2B and CHD8 overlapped in the GO categories head development and central nervous system development 
(Fig. 2, Supplementary Table S5). Four genes, GRIN2B, SCN2A, DMD and SYP, were found in the GO category 
synaptic membrane. We also observed that ENPP1, IGF1, AGTR2, PLXNA3, DYRK1A and CHD8 were involved 
in the GO category negative regulation of response to stimulus. These results suggested that these particular bio-
logical processes might be related to ASD or other neurological conditions.
Figure 1. Types of validated variants and inheritance modes. (A) The distribution of inheritance modes; 
(B) The distribution of variant types. The values indicate the number of variants, and their percentages are 
presented in parentheses.
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Discussion
The rapidly declining cost of next-generation sequencing in recent years has resulted in many genetic studies of 
neurodegenerative disorders, including ASD58–60. As a result, an increasing number of new genes and variants 
have been found to be enriched in ASD individuals, revealing the highly heterogeneous nature of ASD. In addi-
tion, cutting-edge molecular biology or modelling of ASD allows us to better define and understand the aetiology 
of ASD and biological pathways of associated genes61. In this study, we performed whole exome sequencing of 
100 Vietnamese children with ASD and their unaffected parents together with analysis of biological processes to 
explore the genetic landscape of ASD in Vietnamese children.
Gender bias between males and females in ASD is generally acknowledged, where males have an approxi-
mately 4-fold higher incidence of ASD than females. Several hypotheses on male bias, such as the nonrecognition 
of females with ASD62,63, differences in brain structure and genetic load between females and males64 and female 
protective effect against autistic behaviour65, have been proposed. It is hypothesized that females carry a higher 
genetic load and are thus less vulnerable to ASD from genetic causes than males66. Meanwhile, de novo variations 
are strongly associated with ASD, suggesting that females have a greater resistance to de novo variations than 
males67,68. Our findings with a predominance of males over females (4.9-fold) are consistent with those from 
previous studies65,69–71. Moreover, the results of all X-linked variants detected in affected males further supported 
the recent hypothesis of the female protective effect against ASD72.
Regarding the number of de novo variants detected, a previous study using whole genome sequencing from 
the 1902 quartet family with ASD reported 67.1 de novo variants per child’s genome (61 SNV and 5.6 indel DNV 
per child)13. Another study using WES73 detected 0.9 de novo variants per child’s exome (869 SNVs and 27 indel 
de novo variants in a total cohort of 990 ASD samples). In our study, before variant filtering by stringent condi-
tions, we detected 1.3 de novo variants per child’s exome, which was compatible with the results of previous stud-
ies. After filtering, the de novo variant rate in our study was 0.08%, including three missense and five LoF variants 
(three frameshift, one stop gained and one in-frame deletion) (Table 1).
We observed that 11 genes from our cohort have been reported in the autism databases (Table 3). Among 
these genes, CHD8, DYRK1A, GRIN2B, SCN2A, and MDB5 were highly recognized as ASD risk genes with FDR 
<0.1, as previously reported17,18,44,45,74,75. In addition, OFD1 is involved in the Wnt pathway and is highly sug-
gested as an ASD risk gene76. Most of these genes also overlapped in the gene sets of developmental disorders46 or 
EP47. Thus, these genes were highly universal for ASD regardless of population.
Given that ASD is highly genetically heterogeneous, there are several key biological processes involved in the 
development of ASD, including neurogenesis, synaptic plasticity, synaptogenesis and neurite growth8,20,77. Among 
the six newly uncovered genes in this study, we observed that IGF1 and SYP encode proteins involved in brain 
development and synaptic activities, respectively. In addition, a dozen ASD-linked genes are involved in several 
biological processes, such as ribosomal maturation and mRNA regulation, that are linked to synaptic function 
Proband/
Gender Chr Position Gene
Variant Genotype gnomAD MAF (%)
InheritanceSNP ID Base change
Amino acid 
change Proband UM UF pLI/Z score
gnomAD/gnomAD  
East Asia/1000 G
ASD005/M X 79279657 TBX22 rs368136178 c.452 G > T p.Arg151Leu T G/T G 0.98/−0.13 0.007811/0.04724/ 0.0529801 X-linked
ASD006/F 12 102813438 IGF1 . c.251 G > A p.Arg84Gln C/T C/C C/C 0.27/1.54 n/a De novo
ASD032/M 2 149216339 MBD5 . c.14_15delAA p.Lys5fs CAA/C CAA/CAA CAA/CAA 1/1.14 n/a De novo
ASD035/M X 76938776 ATRX . c.1972C > T p.Arg658Cys A G/A G 1/3.1 0.0005476/0.007216 X-linked
ASD038/M 21 38858853 DYRK1A . c.601 C > T p.Gln201* C/T C/C C/C 1/3.34 n/a De novo
ASD046/M
12 13722914 GRIN2B . c.2208dupG p.Asn737fs T/TC T/T T/T 1/5.42 n/a De novo
X 115304290 AGTR2 . c.757 C > T p.Gln253* T C/T C 0.01/−0.07 n/a X-linked
ASD056/M 6 132185700 ENPP1 . c.1081_1083del AAA p.Lys361del TAA/T TAAA/TAAA TAAA/TAAA 0/1.62 n/a De novo
ASD057/M X 32663092 DMD . c.1138 C > T p.His380Tyr A G/A G
1/−2.43
n/a X-linked
ASD059/M X 32490353 DMD . c.2877 A > C p.Glu959Asp G T/T T n/a X-linked
ASD063/M 14 21871315 CHD8 . c.3575 T > C p.Ile1192Thr A/G A/A A/A 1/5.95 n/a De novo
ASD068/F 2 166152561 SCN2A rs34411329 c.232delC p.Leu78fs GC/G GC/GC GC/GC 1/6.46 n/a De novo
ASD076/M
X 49050795 SYP rs782025908 c.251 C > G p.Ala84Gly C G/C G 0.92/1.33 0.0005482/ 0.007216 X-linked
X 64737988 LAS1L . c.1797_1805del TGATGAAGA
p.Asp599_
Glu601del C CTCTTCATCA/C CTCTTCATCA 1/2.67 0.03504/0.05409 X-linked
ASD083/M X 13778788 OFD1 rs778936071 c.2209 A > G p.Thr737Ala G A/G A 0.96/0.32 0.005428/0.07444 X-linked
ASD086/M X 85212934 CHM . c.866 T > C p.Met289Thr G A/G A 1/0.79 0.001099/0 X-linked
ASD097/M 12 60165042 SLC16A7 rs141923225 c.260 C > T p.Pro87Leu C/T C/C C/C 0.01/0.28 0.001598/0 De novo
ASD099/M X 153693430 PLXNA3 rs201083788 c.2113 C > T p.Arg705Trp T C/T C 0.05/0.68 0.004982/0.06801/ 0.0529801 X-linked
Table 1. Detected variants in 100 Vietnamese children with ASD. Chr (Chromosome); MAF represents the 
minor allele frequency that appeared in gnomAD and 1000 Human Genome Project; n/a (not available); UF 
(unaffected father); UM (unaffected mother).
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and chromosome condensation18,20,78. Defects in genes encoding ribosomal proteins have resulted in downregula-
tion of these genes in children with ASD and healthy woman with autistic children79. Therefore, defects of LAS1L, 
which plays a role in ribosome biogenesis, likely lead to a disruption of ribosomal maturation.
We found 18 unique variants in 17 genes from 16 unrelated probands. Biological analysis showed that many of 
these genes were involved in neuronal activities and formation. Together with previously ASD-linked genes, other 
newly detected genes in this study, including IGF1, LAS1L and SYP, were found to be plausible ASD-related genes 
due to their involvement in some risk-associated biological processes and their associations with other neurolog-
ical conditions. In general, ASD is a complex disorder showing a broad range of phenotypes, where 35% of ASD 
cases have ID, 5–15% have EP and 50% have language developmental delay22. Therefore, phenotype-genotype 
analysis accompanied by biological process/pathway analysis is critical for the determination of their associations 
with ASD. However, functional studies on these genes in ASD development should be performed.
conclusions
Consistent with previous studies, this study found a predominance of ASD-affected males over affected females 
(4.9-fold). Rett and Fragile-X syndrome are the most common comorbidities with ASD, but there was no indi-
vidual in our cohort with these syndromes. With a stringent pipeline, we finally identified 18 unique variants that 
occurred in 17 genes, of which 12 variants were reported for the first time. All X-linked variants were detected 
in male probands but not in affected females. This finding is consistent with a contribution of X-linked recessive 
variants to ASD. We found 11 genes formally associated with ASD, some of which have been previously identified 
as ASD risk genes (CHD8, DYRK1A, GRIN2B, SCN2A, OFD1 and MDB5), indicating the genetic universal aetiol-
ogy of ASD. Interestingly, this study uncovered variants in six new candidate genes (CHM, ENPP1, IGF1, LAS1L, 
SYP and TBX22) enriched in our ASD cohort. Analyses of phenotype-genotype and GO showed that many of our 
detected genes were associated with several neurological conditions and were involved in some neuronal biolog-
ical processes, such as synaptic processes, regulation of transport and ribosome maturation. We conferred that 
genetic predispositions in these genes might be causative factors. This study is the first to elucidate the common 
and unique genetic landscape of ASD in Vietnamese children.
Methods
Ethics statement. The study protocol was approved by the Ethical Committee of Vinmec International 
Hospital in accordance with the Declaration of Helsinki. Before the enrolments, written informed consent forms 
including the use of peripheral blood and clinical data for research use and publication were obtained from the 
parents.
Proband 
(Gender) Gene
Variant In silico prediction
Impact Type of variantBase change Amino acid change
CADD 
score 
(scaled)
PolyPhen-2 
(score)
Mutation 
Taster 
(score)
SIFT 
(score)
ASD005/M TBX22 c.452 G > T p.Arg151Leu 24.9 P(0.703) D(1) D(0.001) Moderate Missense
ASD006/F IGF1 c.251 G > A p.Arg84Gln 27.2 D(0.998) D(1) D(0.001) Moderate Missense
ASD032/M MBD5 c.14_15delAA p.Lys5fs D(1) High Frameshift
ASD035/M ATRX c.1972C > T p.Arg658Cys 24.7 D(0.993) D(1) D(0) Moderate Missense
ASD038/M DYRK1A c.601 C > T p.Gln201* 37 A(1) High Stop gained
ASD046/M
GRIN2B c.2208dupG p.Asn737fs High Frameshift
AGTR2 c.757 C > T p.Gln253* 36 D(1) High Stop gained
ASD056/M ENPP1 c.1081_1083delAAA p.Lys361del D(0.547) Moderate In-frame deletion
ASD057/M DMD c.1138 C > T p.His380Tyr 24.5 D(0.994) D(0.999) D(0.015) Moderate Missense
ASD059/M DMD c.2877 A > C p.Glu959Asp 24.5 D(0.0999) Moderate Missense
ASD063/M CHD8 c.3575 T > C p.Ile1192Thr 27.1 D(0.948) D(1) D(0) Moderate Missense
ASD068/F SCN2A c.232delC p.Leu78fs D(1) High Frameshift
ASD076/M
SYP c.251 C > G p.Ala84Gly 25.3 P(0.816) D(1) D(0.002) Moderate Missense
LAS1L c.1797_1805delTGATGAAGA p.Asp599_Glu601del Moderate In-frame deletion
ASD083/M OFD1 c.2209 A > G p.Thr737Ala 24 D(0.997) D(0.943) D(0.005) Moderate Missense
ASD086/M CHM c.866 T > C p.Met289Thr 24.5 B(0.322) D(1) D(0.013) Moderate Missense
ASD097/M SLC16A7 c.260 C > T p.Pro87Leu 24.5 B(0.427) D(1) D(0.035) Moderate Missense
ASD099/M PLXNA3 c.2113 C > T p.Arg705Trp 27.2 P(0.772) D(1) D(0) Moderate Missense
Table 2. In silico predictions of identified variants. Impact of variants predicted by PholyPhen-2, SIFT, 
MutationTaster and CADD where the symbol and the score in the parentheses indicate the impact. PolyPhen-2 
includes three categories (B: benign; P: possibly damaging; D: damaging; score value close to 1 indicates likely 
damaging/deleterious); SIFT (D: damaging; T: tolerated; score value <0.05 is likely damaging/deleterious); 
MutationTaster (A: disease causing automatic; D: disease causing; N: polymorphism; P: polymorphism 
automatic; score value close to 1 shows a high security of the prediction); CADD (scaled score; the higher the 
value, the more deleterious the mutation is).
6Scientific RepoRtS |         (2020) 10:5034  | https://doi.org/10.1038/s41598-020-61695-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
GENE HGNC Encoding protein; function Biological process; Pathway
SFARI 
(score) AutDB
AutismKB 
(syndromic) HPO
Linked to 
ASD or other 
neurological 
disorders
AGTR2 338 Angiotensin II receptor type 2
Blood circulation; Cellular 
response to peptide hormone 
stimulus; Inflammatory 
response; Regulation of 
anatomical structure size
+ (4) + + n/a X-linked MR 88, EP
ATRX 886
Transcriptional regulator 
ATRX; Involvement in the gene 
regulation at interphase and 
chromosomal segregation in 
mitosis
n/a + (4) + +
Alpha-thalassemia, MR 
syndrome, X-linked, 
Myelodysplasia, 
Neuroendocrine tumour of 
stomach
ASD, DD, 
EP, ID
CHD8 20153
Chromodomain helicase DNA 
binding protein 8; Transcriptional 
regulation, epigenetic 
remodelling, promotion of cell 
proliferation, and regulation of 
RNA synthesis
Wnt signalling + (1 S)  + ASD ASD, DD, ID, ADHD, SCZ
CHM 1940
Rab proteins 
geranylgeranyltransferase 
component A1; Involved in 
geranylgeranyl transfer reaction
Intracellular protein 
transport; Intracellular 
signal transduction; 
Nervous system process; 
Neurotransmitter secretion; 
Vesicle-mediated transport
Choroideremia
DMD 2928
Dystrophin; Bridging the inner 
cytoskeleton and the extracellular 
matrix
Muscle fibre and organ 
development, positive 
regulation of neuron 
differentiation, neuron 
projection development, 
extracellular matrix
+ (S) +
Becker/ Duchene muscular 
dystrophy, cardiomyopathy 
dilated X-linked type 3B
ASD, ADHD, 
DD, EP, ID, 
SCZ
DYRK1A 3091
Dual specificity tyrosine-
phosphorylation-regulated kinase 
1A; Cell proliferation, brain 
development.
Cell cycles, miotic G1-G1/S 
phases + (1 S) +
MR autosomal dominant 
type 7
ASD, DD, 
EP, ID
ENPP1 3356 Ectonucleotide pyrophosphatase/phosphodiesterase 1
ATP metabolic process; 
Biomineral tissue 
development; Cell 
differentiation; Inorganic 
anion transport; Nucleoside 
triphosphate catabolic 
process; Ossification
Hypophosphatemic rickets; 
Arterial calcification; Diabetes; 
Pseudoxanthoma Elasticum; 
Obesity; Cole disease
GRIN2B 4586
Glutamate ionotropic receptor 
NMDA type subunit 2B; Brain 
development, circuit formation, 
synaptic plasticity, cellular 
migration and differentiation.
+ (1) + MR; West syndrome; Epileptic encephalopathy
ASD, ADHD, 
DD, EP, ID, 
SCZ.
IGF1 5464
Insulin-like growth factor I; 
Involved in mediating growth and 
development.
Insulin/IGF pathway Insulin-like growth factor I deficiency
LAS1L 25726 LAS1 like, ribosome biogenesis factor
Maturation of 5.8 S rRNA; 
Maturation of LSU-rRNA
Wilson-Turner X-linked MR 
syndrome
MBD5 20444
Methyl-CpG binding domain 
protein 5; Involved in cell division, 
growth and differentiation.
Post-translational protein 
modification; Metabolism of 
proteins
+ (4) + + 2q23.1 microdeletion syndrome
ASD; ADHD, 
DD, EP, ID, 
SCZ
OFD1 2567 OFD1, centriole and centriolar satellite protein
Cell cycle; Centrosome 
maturation; Signalling 
by Hedgehog; Organelle 
biogenesis and maintenance
+ (4) +
Primary ciliary dyskinesia; 
Oral-facial-digital syndrome 
type 1; Simpson-Golabi-
Behmel syndrome type 2; 
Joubert syndrome type 10
ASD
PLXNA3 9101 Plexin A3
Axon guidance; Cell 
adhesion and migration; Cell 
surface receptor signalling 
pathway; Regulation of 
GTPase activity
+ (4) + n/a ASD
SCN2A 10588
Sodium voltage-gated channel 
alpha subunit 2; Involved in the 
generation and propagation of 
action potentials in neurons and 
muscle
Action potential; Chemical 
synaptic transmission; 
Nervous system process
+ (1) +
Seizures; Benign familial 
neonatal infantile; Epileptic 
encephalopathy;Dravet 
syndrome; West syndrome
ASD, ADHD, 
DD, EP, ID
SLC16A7 10928 Solute carrier family 16 member 7
Transport of bile salts and 
organic acids, metal ions and 
amine compounds
+ (5) + n/a ASD
SYP 11506 Synaptophysin Synaptic vesicle trafficking X-linked non-syndromic ID;
TBX22 11600
T-box transcription factor; 
Involved in the regulation of 
developmental processes
Regulation of transcription 
by RNA polymerase II; 
Transcription by RNA 
polymerase II
Cleft palate; X-linked; Charge-
like syndrome; Abruzzo-
Erickson syndrome
Table 3. ASD-associated genes, biological function and phenotype analysis. Reported genes in the database 
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Study cohort and sample collection. Children with suspected ASD were independently examined 
by trained physicians and psychologists at Vinmec Times City International Hospital, Hanoi, Vietnam, using 
the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)1, the Autism Diagnostic 
Observation Schedule (ADOS)80, and Childhood Autism Rating Scale (CARS)81. DSM-V classified the severity of 
ASD into three levels: Level 1 (requiring support), Level 2 (requiring substantial support) and Level 3 (requiring 
very substantial support). To examine the development of the probands, the Denver Developmental Screening 
test II82 (Denver II) was used. Development of the proband (in months) was examined based on five domains: 
personal-social, fine motor, gross motor, understanding and language. The developmental quotient (DQ) was 
calculated by dividing the average developmental age from five domains by the chronological age of the proband 
and multiplying by 100. Definitively diagnosed children with ASD and their unaffected parents were recruited 
to participate in the study. Approximately 3–4 mL of peripheral blood from children with ASD and their unaf-
fected parents was collected and kept in EDTA tubes. Genomic DNA was extracted by using a QIAamp Blood Kit 
(Qiagen, Germany) and stored at −80 °C before use.
Screening of Fragile-X and RETT syndrome. Fragile-X and Rett syndrome are the most common causes 
of inherited mental retardation and are reportedly linked to ASD. Therefore, this study aimed to exclude patients 
with either Fragile-X or Rett syndrome. An AmplideX FMR1 PCR kit (Asuragen, TX, USA) was used for screen-
ing Fragile-X syndrome. Genotypes were determined by examining the size of the trinucleotide repeat segment 
and the methylation status of the FMR1 gene. Since Rett syndrome is predominantly found in females due to the 
mutations in the MECP2 gene, all females diagnosed with ASD were selected for screening for mutations in exons 
2, 3 and 4 of the MECP2 gene83. A detailed method and primer list for MECP2 mutation screening can be found 
in our previous study84. Direct sequencing was performed on an ABI 3500 DX system as indicated hereinafter.
are indicated as “+” symbol; Scores of the ASD genes in SFARI are presented in the parentheses: Syndromic 
ASD (S); High confidence, syndromic (1 S); High confidence (1); Strong candidate (2) Suggestive evidence (3); 
Minimal evidence (4); Hypothesized (5); Not supported (6); and “no rating”. ASD (Autism spectrum disorder); 
ADHD (Attention-deficit/hyperactivity disorder); BPD (Bipolar disorder); DD (Developmental delay); EP 
(Epilepsy); ID (Intellectual disability); MR (Mental retardation); SCZ (Schizophrenia); n/a (not available); HPO 
(Human phenotype ontology).
Figure 2. Gene ontology analysis. Candidate genes and the gene sets are listed in the vertical line and in the 
upper horizontal line, respectively.
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Whole exome sequencing. Probands without mutations detected in the MECP2 and FMR1 genes and 
their biological self-claimed parents were selected for the WES experiment. A DNA library was constructed by 
using a Nextera Rapid Capture Exome Kit (Illumina, USA) capturing over 98% of the exonic contents. The library 
concentration was quantified by a Qubit dsDNA Broad Range Assay Kit (Invitrogen, USA). Library size was 
measured by a Lab Chip 3 K Hisense Kit (Perkin Elmer, USA). Paired-end exome sequencing with a read length 
of 75 × 2 bp was performed on a HiSeq. 4000 (Illumina, USA).
Data analysis. Adapters were removed prior to downstream analysis. BWA version 0.7.15 was used for align-
ment against the human reference genome version GRCh3785. Short, index and mark duplicates were assessed 
by using Samtool version 1.386 and Picard version 2.7.2 (http://broadinstitute.github.io/picard/). GATK toolkit 
version 3.687 and Platypus version 0.8.188 were used to call variants (single nucleotide variants and indels with 
less than 50 bp). Variants were considered highly reliable if they were called by both GATK and Platypus with a 
Phred-score of equal or greater than 30. The minor allele frequency (MAF) was attained from the 1000 Human 
Genome Project89 and gnomAD database (https://gnomad.broadinstitute.org/). Biological relatedness was ana-
lysed by using Peddy software version v0.4.390. Trio samples with non-biological relatedness were excluded from 
the downstream analyses.
Variant classification. Variants were annotated by SnpEff programme version 4.3g91 and fulfilled the fol-
lowing criteria: (i) variant with MAF <0.1%92 against gnomAD, gnomAD East Asia, and 1000 Human Genomes 
Project; (ii) variant passed the GATK standard filters; (iii) nonsynonymous variants including missense variants 
with a prediction of damaging impact and LoF variants (nonsense, frameshift and splicing variants); and (iv) vari-
ant occurred in genes recorded in the DECIPHER and/or SFARI databases. Putative de novo variants were consid-
ered if independent reads in all family members were ≥20 and if both parents were homozygous for the reference 
and the offspring was heterozygous; an X-linked variant was considered if it occurred on the X chromosome.
In silico prediction, gene function and biological process. PolyPhen-2 version 2.293, SIFT version 
4.094 and MutationTaster95 were employed to predict the damaging impact of the missense variants. Combined 
Annotation-Dependent Depletion (CADD) GRCh37-v.14 was used to score the deleteriousness of variants 
with a single nucleotide change96. Gene function, protein class and biological process were determined by 
the PANTHER classification system v.1497. Validated gene sets were computed with the Molecular Signatures 
Database (MSigDB) v6.298,99 to further explore the gene ontology of the ASD candidate genes. Human Phenotype 
Ontology (HPO-Web version 1.5.0)100 was used to find the association of candidate genes with human diseases.
Variant validation. After the stringent filtering strategy, the identified variants were validated by Sanger 
sequencing. Proper primers were designed for each variant by using Primer3Plus software101. Fresh DNA was 
newly extracted from stored blood samples by using the same DNA extraction protocol. Target fragments were 
amplified by GoTaq DNA polymerase (Promega, USA). The amplicons were sequenced on an ABI 3500 DX sys-
tem using a BigDye Terminator v3.1 (Thermo Fisher Scientific, USA). Both forward and reverse read alignment 
were used to determine the sequence.
Data availability
Sequencing data generated and analysed in this study are included in this article and its Supplementary 
Information.
Received: 10 July 2019; Accepted: 18 February 2020;
Published: xx xx xxxx
References
 1. Association, A. P. Diagnostic and Statistical Manual of Mental Disorders. 5 edn, Vol. 2017 (American Psychiatric Association, 2013).
 2. Perou, R. et al. Mental health surveillance among children–United States, 2005-2011. MMWR Suppl. 62, 1–35 (2013).
 3. Amiet, C. et al. Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. Biol. 
Psychiatry 64, 577–582, https://doi.org/10.1016/j.biopsych.2008.04.030 (2008).
 4. Kim, Y. S. et al. Prevalence of autism spectrum disorders in a total population sample. Am. J. Psychiatry 168, 904–912, https://doi.
org/10.1176/appi.ajp.2011.10101532 (2011).
 5. Liu, X., Hubbard, J. A., Fabes, R. A. & Adam, J. B. Sleep disturbances and correlates of children with autism spectrum disorders. 
Child. Psychiatry Hum. Dev. 37, 179–191, https://doi.org/10.1007/s10578-006-0028-3 (2006).
 6. Krakowiak, P., Goodlin-Jones, B., Hertz-Picciotto, I., Croen, L. A. & Hansen, R. L. Sleep problems in children with autism spectrum 
disorders, developmental delays, and typical development: a population-based study. J. Sleep. Res. 17, 197–206, https://doi.
org/10.1111/j.1365-2869.2008.00650.x (2008).
 7. Besag, F. M. Epilepsy in patients with autism: links, risks and treatment challenges. Neuropsychiatr. Dis. Treat. 14, 1–10, https://doi.
org/10.2147/NDT.S120509 (2017).
 8. Huguet, G., Ey, E. & Bourgeron, T. The genetic landscapes of autism spectrum disorders. Annu. Rev. Genomics Hum. Genet. 14, 
191–213, https://doi.org/10.1146/annurev-genom-091212-153431 (2013).
 9. Baio, J. et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities 
Monitoring Network, 11 Sites, United States, 2014. MMWR Surveill. Summ. 67, 1–23, https://doi.org/10.15585/mmwr.ss6706a1 
(2018).
 10. Devlin, B. & Scherer, S. W. Genetic architecture in autism spectrum disorder. Curr. Opin. Genet. Dev. 22, 229–237, https://doi.
org/10.1016/j.gde.2012.03.002 (2012).
 11. Klei, L. et al. Common genetic variants, acting additively, are a major source of risk for autism. Mol. Autism 3, 9, https://doi.
org/10.1186/2040-2392-3-9 (2012).
 12. Gaugler, T. et al. Most genetic risk for autism resides with common variation. Nat. Genet. 46, 881–885, https://doi.org/10.1038/
ng.3039 (2014).
9Scientific RepoRtS |         (2020) 10:5034  | https://doi.org/10.1038/s41598-020-61695-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 13. An, J.-Y. et al. Genome-wide de novo risk score implicates promoter variation in autism spectrum disorder. Sci. 362, eaat6576, 
https://doi.org/10.1126/science.aat6576 (2018).
 14. Turner, T. N. et al. Genomic Patterns of De Novo Mutation in Simplex Autism. Cell 171, 710–722 e712, https://doi.org/10.1016/j.
cell.2017.08.047 (2017).
 15. O’Roak, B. J. et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Sci. 338, 1619, 
https://doi.org/10.1126/science.1227764 (2012).
 16. Yuen, R. K. C. et al. Whole-genome sequencing of quartet families with autism spectrum disorder. Nat. Med. https://doi.
org/10.1038/nm.3792 (2015).
 17. Betancur, C. Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still 
counting. Brain Res. 1380, 42–77, https://doi.org/10.1016/j.brainres.2010.11.078 (2011).
 18. De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nat. 515, 209–215, https://doi.org/10.1038/
nature13772 (2014).
 19. Park, H. R. et al. A Short Review on the Current Understanding of Autism Spectrum Disorders. Exp. Neurobiol. 25, 1–13, https://
doi.org/10.5607/en.2016.25.1.1 (2016).
 20. Gilbert, J. & Man, H. Y. Fundamental Elements in Autism: From Neurogenesis and Neurite Growth to Synaptic Plasticity. Front. 
Cell Neurosci. 11, 359, https://doi.org/10.3389/fncel.2017.00359 (2017).
 21. Ramaswami, G. & Geschwind, D. H. Genetics of autism spectrum disorder. Handb. Clin. Neurol. 147, 321–329, https://doi.
org/10.1016/b978-0-444-63233-3.00021-x (2018).
 22. Geschwind, D. H. & State, M. W. Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet Neurol. 14, 
1109–1120, https://doi.org/10.1016/s1474-4422(15)00044-7 (2015).
 23. Rylaarsdam, L. & Guemez-Gamboa, A. Genetic Causes and Modifiers of Autism Spectrum Disorder. Front. Cell Neurosci. 13, 385, 
https://doi.org/10.3389/fncel.2019.00385 (2019).
 24. Robert, C. et al. Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy. Int J 
Mol Sci 18, https://doi.org/10.3390/ijms18030618 (2017).
 25. Vorstman, J. A. S. et al. Autism genetics: opportunities and challenges for clinical translation. Nat. Rev. Genet. 18, 362–376, https://
doi.org/10.1038/nrg.2017.4 (2017).
 26. Hossain, M. D. et al. Autism Spectrum disorders (ASD) in South Asia: a systematic review. BMC Psychiatry 17, 281, https://doi.
org/10.1186/s12888-017-1440-x (2017).
 27. Wang, F. et al. The prevalence of autism spectrum disorders in China: a comprehensive meta-analysis. Int. J. Biol. Sci. 14, 717–725, 
https://doi.org/10.7150/ijbs.24063 (2018).
 28. Sun, X. & Allison, C. A review of the prevalence of Autism Spectrum Disorder in Asia. Res. Autism Spectr. Disord. 4, 156–167, 
https://doi.org/10.1016/j.rasd.2009.10.003 (2010).
 29. Hoang, V. M. et al. Prevalence of autism spectrum disorders and their relation to selected socio-demographic factors among 
children aged 18–30 months in northern Vietnam, 2017. Int. J. Ment. Health Syst. 13, 29, https://doi.org/10.1186/s13033-019-0285-
8 (2019).
 30. Mpaka, D. M. et al. Prevalence and comorbidities of autism among children referred to the outpatient clinics for 
neurodevelopmental disorders. Pan Afr Med J 25, https://doi.org/10.11604/pamj.2016.25.82.4151 (2016).
 31. Brugha, T. S. et al. Epidemiology of autism spectrum disorders in adults in the community in England. Arch. Gen. Psychiatry 68, 
459–465, https://doi.org/10.1001/archgenpsychiatry.2011.38 (2011).
 32. Zaroff, C. M. & Uhm, S. Y. Prevalence of autism spectrum disorders and influence of country of measurement and ethnicity. Soc. 
Psychiatry Psychiatr. Epidemiol. 47, 395–398, https://doi.org/10.1007/s00127-011-0350-3 (2012).
 33. Thomas, P. et al. The association of autism diagnosis with socioeconomic status. Autism 16, 201–213, https://doi.
org/10.1177/1362361311413397 (2012).
 34. Russell, G., Steer, C. & Golding, J. Social and demographic factors that influence the diagnosis of autistic spectrum disorders. Soc. 
Psychiatry Psychiatr. Epidemiol. 46, 1283–1293, https://doi.org/10.1007/s00127-010-0294-z (2011).
 35. Liu, K.-Y., King, M. & Bearman, P. S. Social influence and the autism epidemic. AJS; Am. J. Sociol. 115, 1387–1434, https://doi.
org/10.1086/651448 (2010).
 36. Mazurek, M. O. et al. Age at first autism spectrum disorder diagnosis: the role of birth cohort, demographic factors, and clinical 
features. J. Dev. Behav. Pediatr. 35, 561–569, https://doi.org/10.1097/dbp.0000000000000097 (2014).
 37. Loomes, R., Hull, L. & Mandy, W. P. L. What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and 
Meta-Analysis. J. Am. Acad. Child. Adolesc. Psychiatry 56, 466–474, https://doi.org/10.1016/j.jaac.2017.03.013 (2017).
 38. Werling, D. M. & Geschwind, D. H. Sex differences in autism spectrum disorders. Curr. Opin. Neurol. 26, 146–153, https://doi.
org/10.1097/WCO.0b013e32835ee548 (2013).
 39. Niu, M. et al. Autism Symptoms in Fragile X Syndrome. J. Child. Neurol. 32, 903–909, https://doi.org/10.1177/0883073817712875 
(2017).
 40. Devitt, N. M., Gallagher, L. & Reilly, R. B. Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS): Two Overlapping 
Disorders Reviewed through Electroencephalography-What Can be Interpreted from the Available Information? Brain Sci. 5, 
92–117, https://doi.org/10.3390/brainsci5020092 (2015).
 41. Crawford, D. C., Acuna, J. M. & Sherman, S. L. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 
3, 359–371, 10.109700125817-200109000-00006 (2001).
 42. Basu, S. N., Kollu, R. & Banerjee-Basu, S. AutDB: a gene reference resource for autism research. Nucleic Acids Res. 37, D832–D836, 
https://doi.org/10.1093/nar/gkn835 (2009).
 43. Yang, C. et al. AutismKB 2.0: a knowledgebase for the genetic evidence of autism spectrum disorder. Database 2018, https://doi.
org/10.1093/database/bay106 (2018).
 44. Sanders, S. J. et al. Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. Neuron 87, 
1215–1233, https://doi.org/10.1016/j.neuron.2015.09.016 (2015).
 45. Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the 
neurobiology of autism. bioRxiv. https://www.biorxiv.org/content/ https://doi.org/10.1101/484113v3 (2019).
 46. Deciphering Developmental Disorders, S. Prevalence and architecture of de novo mutations in developmental disorders. Nature 
542, 433–438, https://doi.org/10.1038/nature21062 (2017).
 47. Heyne, H. O. et al. De novo variants in neurodevelopmental disorders with epilepsy. Nat. Genet. 50, 1048–1053, https://doi.
org/10.1038/s41588-018-0143-7 (2018).
 48. Woods, K. A., Camacho-Hubner, C., Savage, M. O. & Clark, A. J. Intrauterine growth retardation and postnatal growth failure 
associated with deletion of the insulin-like growth factor I gene. N. Engl. J. Med. 335, 1363–1367, https://doi.org/10.1056/
nejm199610313351805 (1996).
 49. Walenkamp, M. J. et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J. Clin. 
Endocrinol. Metab. 90, 2855–2864, https://doi.org/10.1210/jc.2004-1254 (2005).
 50. Hu, H. et al. X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes. Mol. Psychiatry 21, 
133–148, https://doi.org/10.1038/mp.2014.193 (2016).
 51. Butterfield, R. J. et al. Congenital lethal motor neuron disease with a novel defect in ribosome biogenesis. Neurol. 82, 1322–1330, 
https://doi.org/10.1212/wnl.0000000000000305 (2014).
1 0Scientific RepoRtS |         (2020) 10:5034  | https://doi.org/10.1038/s41598-020-61695-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 52. Tarpey, P. S. et al. A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat. Genet. 
41, 535–543, https://doi.org/10.1038/ng.367 (2009).
 53. Pinto, D. et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nat. 466, 368–372, https://
doi.org/10.1038/nature09146 (2010).
 54. Shcheglovitov, A. et al. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nat. 503, 
267–271, https://doi.org/10.1038/nature12618 (2013).
 55. Kwon, S. E. & Chapman, E. R. Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons. Neuron 70, 
847–854, https://doi.org/10.1016/j.neuron.2011.04.001 (2011).
 56. Castle, C. D., Cassimere, E. K., Lee, J. & Denicourt, C. Las1L is a nucleolar protein required for cell proliferation and ribosome 
biogenesis. Mol. Cell Biol. 30, 4404–4414, https://doi.org/10.1128/MCB.00358-10 (2010).
 57. Castle, C. D., Cassimere, E. K. & Denicourt, C. LAS1L interacts with the mammalian Rix1 complex to regulate ribosome biogenesis. 
Mol. Biol. Cell 23, 716–728, https://doi.org/10.1091/mbc.E11-06-0530 (2012).
 58. Keogh, M. J. & Chinnery, P. F. Next generation sequencing for neurological diseases: new hope or new hype? Clin. Neurol. 
Neurosurg. 115, 948–953, https://doi.org/10.1016/j.clineuro.2012.09.030 (2013).
 59. Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. 
Genet. 17, 333, https://doi.org/10.1038/nrg.2016.49 (2016).
 60. Sener, E. F., Canatan, H. & Ozkul, Y. Recent Advances in Autism Spectrum Disorders: Applications of Whole Exome Sequencing 
Technology. Psychiatry Investig. 13, 255–264, https://doi.org/10.4306/pi.2016.13.3.255 (2016).
 61. Guerreiro, R., Bras, J., Hardy, J. & Singleton, A. Next generation sequencing techniques in neurological diseases: redefining clinical 
and molecular associations. Hum. Mol. Genet. 23, R47–53, https://doi.org/10.1093/hmg/ddu203 (2014).
 62. Milner, V., McIntosh, H., Colvert, E. & Happe, F. A Qualitative Exploration of the Female Experience of Autism Spectrum Disorder 
(ASD). J Autism Dev Disord, https://doi.org/10.1007/s10803-019-03906-4 (2019).
 63. Bargiela, S., Steward, R. & Mandy, W. The Experiences of Late-diagnosed Women with Autism Spectrum Conditions: An 
Investigation of the Female Autism Phenotype. J. Autism Dev. Disord. 46, 3281–3294, https://doi.org/10.1007/s10803-016-2872-8 
(2016).
 64. Baron-Cohen, S. et al. Why are autism spectrum conditions more prevalent in males? PLoS Biol. 9, e1001081, https://doi.
org/10.1371/journal.pbio.1001081 (2011).
 65. Robinson, E. B., Lichtenstein, P., Anckarsäter, H., Happé, F. & Ronald, A. Examining and interpreting the female protective effect 
against autistic behavior. Proc. Natl Acad. Sci. USA 110, 5258–5262, https://doi.org/10.1073/pnas.1211070110 (2013).
 66. Levy, D. et al. Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron 70, 886–897, https://doi.
org/10.1016/j.neuron.2011.05.015 (2011).
 67. Sebat, J. et al. Strong association of de novo copy number mutations with autism. Sci. 316, 445–449, https://doi.org/10.1126/
science.1138659 (2007).
 68. Sanders, S. J. et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nat. 485, 237–241, 
https://doi.org/10.1038/nature10945 (2012).
 69. Szatmari, P. et al. Sex differences in repetitive stereotyped behaviors in autism: implications for genetic liability. Am. J. Med. Genet. 
B Neuropsychiatr. Genet 159B, 5–12, https://doi.org/10.1002/ajmg.b.31238 (2012).
 70. Taylor, M. J. et al. Is There a Female Protective Effect Against Attention-Deficit/Hyperactivity Disorder? Evidence From Two 
Representative Twin Samples. J. Am. Acad. Child. Adolesc. Psychiatry 55, 504–512 e502, https://doi.org/10.1016/j.jaac.2016.04.004 
(2016).
 71. Jacquemont, S. et al. A higher mutational burden in females supports a “female protective model” in neurodevelopmental 
disorders. Am. J. Hum. Genet. 94, 415–425, https://doi.org/10.1016/j.ajhg.2014.02.001 (2014).
 72. Skuse, D. H. Imprinting, the X-chromosome, and the male brain: explaining sex differences in the liability to autism. Pediatr. Res. 
47, 9–16 (2000).
 73. Werling, D. M. et al. An analytical framework for whole-genome sequence association studies and its implications for autism 
spectrum disorder. Nat. Genet. 50, 727–736, https://doi.org/10.1038/s41588-018-0107-y (2018).
 74. Neale, B. M. et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nat. 485, 242–245, https://doi.
org/10.1038/nature11011 (2012).
 75. O’Roak, B. J. et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat. Genet. 43, 
585–589, https://doi.org/10.1038/ng.835 (2011).
 76. Li, J. et al. Targeted sequencing and functional analysis reveal brain-size-related genes and their networks in autism spectrum 
disorders. Mol. Psychiatry 22, 1282–1290, https://doi.org/10.1038/mp.2017.140 (2017).
 77. Subramanian, M., Timmerman, C. K., Schwartz, J. L., Pham, D. L. & Meffert, M. K. Characterizing autism spectrum disorders by 
key biochemical pathways. Front. Neurosci 9, https://doi.org/10.3389/fnins.2015.00313 (2015).
 78. Darnell, J. C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247–261, 
https://doi.org/10.1016/j.cell.2011.06.013 (2011).
 79. Kuwano, Y. et al. Autism-associated gene expression in peripheral leucocytes commonly observed between subjects with autism 
and healthy women having autistic children. PLoS One 6, e24723, https://doi.org/10.1371/journal.pone.0024723 (2011).
 80. Lord, C. et al. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J. Autism 
Dev. Disord. 19, 185–212, https://doi.org/10.1007/bf02211841 (1989).
 81. Schopler, E., Reichler, R. J., DeVellis, R. F. & Daly, K. Toward objective classification of childhood autism: Childhood Autism Rating 
Scale (CARS). J. Autism Dev. Disord. 10, 91–103, https://doi.org/10.1007/bf02408436 (1980).
 82. Frankenburg, W. K., Dodds, J., Archer, P., Shapiro, H. & Bresnick, B. The Denver II: a major revision and restandardization of the 
Denver Developmental Screening Test. Pediatrics 89, 91–97 (1992).
 83. Saunders, C. J., Minassian, B. E., Chow, E. W. C., Zhao, W. & Vincent, J. B. Novel exon 1 mutations in MECP2 implicate isoform 
MeCP2_e1 in classical Rett syndrome. Am. J. Med. Genet. A 149A, 1019–1023, https://doi.org/10.1002/ajmg.a.32776 (2009).
 84. Le Thi Thanh, H. et al. Spectrum of MECP2 mutations in Vietnamese patients with RETT syndrome. BMC Med. Genet. 19, 137, 
https://doi.org/10.1186/s12881-018-0658-x (2018).
 85. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinforma. 25, 1754–1760, https://
doi.org/10.1093/bioinformatics/btp324 (2009).
 86. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics, https://doi.org/10.1093/bioinformatics/btp352 
(2009).
 87. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. 
Genome Res. 20, 1297–1303, https://doi.org/10.1101/gr.107524.110 (2010).
 88. Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing 
applications. Nat. Genet. 46, 912, https://doi.org/10.1038/ng.3036 (2014).
 89. Auton, A. et al. A global reference for human genetic variation. Nat. 526, 68–74, https://doi.org/10.1038/nature15393 (2015).
 90. Pedersen, B. S. & Quinlan, A. R. Who’s Who? Detecting and Resolving Sample Anomalies in Human DNA Sequencing Studies with 
Peddy. Am. J. Hum. Genet. 100, 406–413, https://doi.org/10.1016/j.ajhg.2017.01.017 (2017).
 91. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the 
genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 6, 80–92, https://doi.org/10.4161/fly.19695 (2012).
1 1Scientific RepoRtS |         (2020) 10:5034  | https://doi.org/10.1038/s41598-020-61695-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
 92. Kosmicki, J. A. et al. Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population 
reference samples. Nat. Genet. 49, 504–510, https://doi.org/10.1038/ng.3789 (2017).
 93. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249, https://doi.
org/10.1038/nmeth0410-248 (2010).
 94. Vaser, R., Adusumalli, S., Leng, S. N., Sikic, M. & Ng, P. C. SIFT missense predictions for genomes. Nat. Protoc. 11, 1–9, https://doi.
org/10.1038/nprot.2015.123 (2016).
 95. Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat. 
Methods 11, 361, https://doi.org/10.1038/nmeth.2890 (2014).
 96. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the deleteriousness of variants throughout 
the human genome. Nucleic Acids Res. 47, D886–D894, https://doi.org/10.1093/nar/gky1016 (2019).
 97. Mi, H. et al. Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). 
Nat. Protoc. 14, 703–721, https://doi.org/10.1038/s41596-019-0128-8 (2019).
 98. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinforma. 27, 1739–1740, https://doi.org/10.1093/
bioinformatics/btr260 (2011).
 99. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425, https://doi.
org/10.1016/j.cels.2015.12.004 (2015).
 100. Köhler, S. et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. Nucleic Acids Res. 47, 
D1018–D1027, https://doi.org/10.1093/nar/gky1105 (2019).
 101. Untergasser, A. et al. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 35, W71–74, https://doi.org/10.1093/
nar/gkm306 (2007).
Acknowledgements
We thank the physicians, particularly Ms. Dang Thi Thanh Tung of the High Technology Unit for Cerebral Palsy 
and Autism, Vinmec Times City International Hospital, for their patient recruitment and assessment. This work 
was financially supported by the Vinmec Health Care system with grant No. ISC17.03.
Author contributions
Conception of the study: L.T.N., K.T.T. and V.S.L. Patient recruitment and assessment: H.T.P.B., D.H.D., L.T.H. 
and H.T.T.L. Whole exome sequencing: K.T.T. and D.M.V. Genetic screening and Sanger sequencing validation: 
H.T.T.L., L.T.H., H.T.N., L.T.M.D. and T.H.N. Bioinformatics analysis: V.S.L. and K.T.T. Data interpretation: 
K.T.T. Manuscript drafting: K.T.T., V.S.L., L.T.N., A.M., H.T.N., L.T.M.D. and T.H.N.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-61695-8.
Correspondence and requests for materials should be addressed to V.S.L. or L.T.N.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
